Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage (Q38335859)

2 September 2017

title

Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage (English)

1 reference

2 September 2017

2

Osheroff N

1 reference

2 September 2017

Fortune JM

1

1 reference

2 September 2017

language of work or name

English

0 references

publication date

1 July 1998

1 reference

Journal of Biological Chemistry

2 September 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

2 September 2017

volume

273

1 reference

2 September 2017

issue

28

1 reference

2 September 2017

page(s)

17643-17650

1 reference

When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Antitopoisomerase drug action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Topoisomerase II enzymes and mutagenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Structure and function of type II DNA topoisomerases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Using yeast to understand drugs that target topoisomerases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Energy coupling in DNA gyrase and the mechanism of action of novobiocin

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

DNA gyrase: subunit structure and ATPase activity of the purified enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

The interaction between coumarin drugs and DNA gyrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Molecular mechanisms of drug inhibition of DNA gyrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

DNA gyrase as a drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Phase II trial of merbarone in soft tissue sarcoma. A Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Topoisomerase II.etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Calcium-promoted DNA cleavage by eukaryotic topoisomerase II: trapping the covalent enzyme-DNA complex in an active form.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Complete Nucleotide Sequence of the Escherichia coli Plasmid pBR322

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Apurinic sites are position-specific topoisomerase II poisons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Drosophila topoisomerase II double-strand DNA cleavage: analysis of DNA sequence homology at the cleavage site

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

The interaction of ethidium with synthetic double-stranded polynucleotides at low ionic strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

5-(N-phenylcarboxamido)-2-thiobarbituric acid (NSC 336628), a novel potential antitumor agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Catalytic function of DNA topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

DNA topoisomerase II as the cellular target of a novel antitumor agent ICRF-193, a bisdioxopiperazine derivative, in Xenopus egg extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Structure and mechanism of DNA topoisomerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Characterization of the interaction between topoisomerase II and DNA by transcriptional footprinting

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

Proteolysis patterns of epitopically labeled yeast DNA topoisomerase II suggest an allosteric transition in the enzyme induced by ATP binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.273.28.17643

21 January 2018

Identifiers

DOI

10.1074/JBC.273.28.17643

1 reference

2 September 2017

1 reference